PL79404B1 - - Google Patents
Download PDFInfo
- Publication number
- PL79404B1 PL79404B1 PL12971468A PL12971468A PL79404B1 PL 79404 B1 PL79404 B1 PL 79404B1 PL 12971468 A PL12971468 A PL 12971468A PL 12971468 A PL12971468 A PL 12971468A PL 79404 B1 PL79404 B1 PL 79404B1
- Authority
- PL
- Poland
- Prior art keywords
- pro
- formula
- meleu
- meval
- leu
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 claims description 4
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 3
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 2
- CCAIIPMIAFGKSI-DMTCNVIQSA-N (2s,3r)-3-hydroxy-2-(methylazaniumyl)butanoate Chemical compound CN[C@@H]([C@@H](C)O)C(O)=O CCAIIPMIAFGKSI-DMTCNVIQSA-N 0.000 claims 1
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DZMGFGQBRYWJOR-YUMQZZPRSA-N Met-Pro Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O DZMGFGQBRYWJOR-YUMQZZPRSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- XJODGRWDFZVTKW-ZCFIWIBFSA-N n-methylleucine Chemical compound CN[C@@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-ZCFIWIBFSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR125842 | 1967-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL79404B1 true PL79404B1 (enExample) | 1975-06-30 |
Family
ID=8640723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12971468A PL79404B1 (enExample) | 1967-10-25 | 1968-10-24 |
Country Status (10)
| Country | Link |
|---|---|
| AT (1) | AT286513B (enExample) |
| BR (2) | BR6803309D0 (enExample) |
| CH (1) | CH490339A (enExample) |
| CS (1) | CS151487B2 (enExample) |
| ES (1) | ES359552A1 (enExample) |
| FI (1) | FI49399C (enExample) |
| FR (1) | FR1578723A (enExample) |
| PL (1) | PL79404B1 (enExample) |
| SU (1) | SU535902A3 (enExample) |
| YU (1) | YU249168A (enExample) |
-
1967
- 1967-10-25 FR FR1578723D patent/FR1578723A/fr not_active Expired
-
1968
- 1968-10-21 BR BR20330968A patent/BR6803309D0/pt unknown
- 1968-10-21 BR BR20331068A patent/BR6803310D0/pt unknown
- 1968-10-24 CH CH1590768A patent/CH490339A/fr not_active IP Right Cessation
- 1968-10-24 PL PL12971468A patent/PL79404B1/pl unknown
- 1968-10-25 AT AT1046168A patent/AT286513B/de not_active IP Right Cessation
- 1968-10-25 CS CS735568A patent/CS151487B2/cs unknown
- 1968-10-25 FI FI303768A patent/FI49399C/fi active
- 1968-10-25 YU YU249168A patent/YU249168A/xx unknown
- 1968-10-25 ES ES359552A patent/ES359552A1/es not_active Expired
- 1968-10-25 SU SU1280361A patent/SU535902A3/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| CH490339A (fr) | 1970-05-15 |
| AT286513B (de) | 1970-12-10 |
| FI49399B (enExample) | 1975-02-28 |
| BR6803309D0 (pt) | 1973-02-22 |
| BR6803310D0 (pt) | 1973-02-22 |
| YU249168A (en) | 1978-05-15 |
| CS151487B2 (enExample) | 1973-10-19 |
| ES359552A1 (es) | 1970-06-01 |
| FI49399C (fi) | 1975-06-10 |
| FR1578723A (enExample) | 1969-08-22 |
| SU535902A3 (ru) | 1976-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2919965B2 (ja) | デヒドロジデムニンｂ | |
| US4288431A (en) | Cyclosporin derivatives, their production and pharmaceutical compositions containing them | |
| US4493796A (en) | Didemnins A, B, C, and derivatives thereof, as antiviral agents | |
| DE69003168T2 (de) | Isolierung und Strukturbestimmung des zytostatischen linearen depsipeptiden Dolastatin 13 und Dehydrodolastatin 13. | |
| US4414205A (en) | Cell growth inhibitory substances | |
| US3992365A (en) | Agonist analogues of luteinizing hormone releasing hormone | |
| US4490291A (en) | Nonapeptide amides | |
| US4466918A (en) | Method of preparing thymosin alpha 1 and derivatives thereof | |
| IE44749B1 (en) | Dihydrocyclosporin c | |
| JPS6340199B2 (enExample) | ||
| GB1586521A (en) | Analgesic tetrapeptides and pentapeptides | |
| EP0001684B1 (en) | Tetrapeptides, methods for their preparation and their use in analgesic compositions | |
| Bevan et al. | Amino-acids and peptides. Part X. Characterisation of the monamycins, members of a new family of cyclodepsipeptide antibiotics | |
| CN101522705B (zh) | 来自actinomadura namibiensis的抗菌和抗病毒肽 | |
| EP0033384B1 (de) | Thymosin-alpha-1-Fragmente enthaltende Arzneimittel mit immunstimulierender Wirkung, und Thymosin-alpha-1-Fragmente | |
| EP0288278A2 (en) | Chemical derivatives of GHL-CU | |
| US4083967A (en) | Nona- and decapeptides | |
| US4512923A (en) | Luteinizing and follicle stimulating hormones and process for the preparation thereof | |
| Teshima et al. | Chemical studies on tuberactinomycin. XII. Syntheses and antimicrobial activities of [Ala3, Ala4]-,[Ala3]-, and [Ala4]-tuberactinomycin O. | |
| IE51967B1 (en) | Novel pentapeptides,processes for their production,pharmaceutical compositions comprising said pentapeptides and their use | |
| SE461042B (sv) | Peptider med tillvaextbefraemjande aktivitet jaemte veterinaera kompositioner innehaallande naemnda peptider | |
| HU193291B (en) | Process for production of biologically active heptapeptides and their acid-additional salts and medical preparatives containing thereof as active substance | |
| US4358440A (en) | Polypeptide and its production and use | |
| US3341510A (en) | L-alanyl-l-phenylalanyl-l-isoleucyl-glycyl-l-leucyl-l-methioninamide and a protectedderivative thereof | |
| Semko et al. | Synthesis and investigation of the antitumoral activity of shortened analogs of luliberin |